<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BENZPHETAMINE HYDROCHLORIDE</span><br/>(benz-fet'a-meen)<br/><span class="topboxtradename">Didrex<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">cerebral stimulant</span>; <span class="classification">anorexiant</span><br/><b>Prototype: </b>Amphetamine<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Indirect acting sympathomimetic amine with amphetamine-like actions but with fewer side effects than amphetamine.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Anorexiant effect thought to be secondary to stimulation of hypothalamus to release stored catecholamines in the CNS.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term adjunct in management of exogenous obesity.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to sympathomimetic amines; angle-closure glaucoma; advanced arteriosclerosis, angina pectoris, severe
         cardiovascular disease, moderate to severe hypertension; hyperthyroidism, agitated states; history of drug abuse; children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Diabetes mellitus; older adults; psychosis.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Obesity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2550 mg 13 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give as a single daily dose, preferably midmorning or midafternoon, according to patient's eating habits.</li>
<li>Schedule daily dose no later than 6 h before patient retires to avoid insomnia.</li>
<li>Store in tight, light-resistant containers at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Euphoria, irritability, hyperactivity, nervousness, <span class="speceff-common">restlessness, insomnia,</span> tremor, headache, light-headedness, dizziness, depression following stimulant effects. <span class="typehead">CV:</span>
<span class="speceff-common">Palpitation,</span> tachycardia, elevated BP, irregular heart beat. <span class="typehead">GI:</span> Xerostomia, nausea, vomiting, diarrhea or constipation, abdominal cramps. <span class="typehead"> Chronic Intoxication:</span> Marked insomnia, irritability, hyperactivity, personality changes, psychosis, severe dermatoses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Acetazolamide,</b>
<b>sodium bicarbonate</b> decrease <span class="classification">amphetamine</span> elimination; <b>ammonium chloride,</b>
<b>ascorbic acid</b> increase <span class="classification">amphetamine</span> elimination; <span class="classification">barbiturates</span> may antagonize the effects of both drugs; <b>furazolidone</b> may increase BP effects of <span class="classification">amphetamines</span>, and interaction may persist for several weeks after discontinuation of <b>furazolidone;</b>
<b>guanethidine,</b>
<b>guanadryl</b> antagonize antihypertensive effects; because <span class="classification">mao inhibitors</span>, <b>selegiline</b> can cause hypertensive crisis (fatalities reported); do not administer <span class="classification">amphetamines</span> during or within 14 d of these drugs; <span class="classification">phenothiazines</span> may inhibit mood-elevating effects of <span class="classification">amphetamines</span>; <span class="classification">tricyclic antidepressants</span> enhance <span class="classification">amphetamine</span> effects because they increase <b>norepinephrine</b> release; <span class="classification">beta agonists</span> increase <span class="classification">amphetamine's</span> adverse cardiovascular effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Duration:</span> 4 h. <span class="typehead">Elimination:</span> Renal elimination. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for signs of excessive CNS stimulation: insomnia, restlessness, tremor, palpitations. These may indicate need for dosage
            adjustment.
         </li>
<li>Monitor vital signs; report elevated BP, tachycardia, and irregular heart rhythm.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Anorexiant effects are temporary and tolerance may occur; long-term use is not indicated.
            						
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not terminate high dosage therapy abruptly; GI distress, stomach cramps, trembling, unusual tiredness, weakness, and mental
            depression may result.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>